Dimethylformamide → (5-((2-Methyl-2-(methyldisulfanyl)propylthio)methyl)-1,3-phenylene)dimethanol
反応式
[CH3:1][C:2]([S:25][S:26][CH3:27])([CH3:24])[CH2:3][S:4][CH2:5][C:6]1[CH:7]=[C:8](CCS([O-])(=O)=O)[CH:9]=[C:10]([CH2:12]CS([O-])(=O)=O)[CH:11]=1.[C:28](=[O:31])([O-])[O-].[K+].[K+].CN(C)C=[O:37]>>[CH3:1][C:2]([S:25][S:26][CH3:27])([CH3:24])[CH2:3][S:4][CH2:5][C:6]1[CH:7]=[C:8]([CH2:28][OH:31])[CH:9]=[C:10]([CH2:12][OH:37])[CH:11]=1参加物
4
実験手順
IBD monomer (177 mg, 0.602 mmol) in anhydrous N,N-dimethylformamide (1.75 mL) was added to (5-((2-methyl-2-(methyldisulfanyl)propylthio)methyl)-1,3-phenylene)bis(methylene)dimethanesulfonate (119 mg, 0.251 mmol) at ambient temperature. Potassium carbonate (173 mg, 1.253 mmol) was added and the reaction was allowed to stir at ambient temperature for 20 hours. The reaction mixture was quenched with water and extracted with dichloromethane. The extracts were washed with brine and then dried with anhydrous sodium sulfate, filtered and concentrated on high vacuum. The crude product was purified by flash silica gel chromatography (neat DCM 2% MeOH/DCM). Fractions containing product were combined, concentrated and purified by semi-prep RP-HPLC (C18, A=DI water B=ACN, 20 mL/min). Fractions containing desired product were combined, extracted with dichloromethane, dried with anhydrous magnesium sulfate, filtered and concentrated to yield the desired product (46 mg, 21%). 1H NMR (400 Hz, CDCl3): δ 8.19 (d, J=8.0 Hz, 2H), 7.77 (m, d, J=4.4 Hz, 2H), 7.50 (s, 2H), 7.34 (s, 1H), 7.31 (s, 2H), 7.19 (m, 4H), 7.03 (t, J=7.2, 7.6 Hz, 2H), 6.77 (s, 2H), 5.14 (m, 4H), 4.40 (m, 2H), 3.91 (s, 6H), 3.70 (m, 2H), 3.63 (m, 2H), 3.41 (m, 2H), 2.65 (s, 2H), 2.29 (s, 3H), 1.26 (s, 6H). MS (m/z), Calcd. 893.2 (M+Na)+; found 893.2 (M+Na)+, 911.2 (M+H2O+Na)+, 929.2 (M+2H2O+Na)+, 945.1 (M+2H2O+K)+. See FIG. 30.